Is GE Healthcare Technologies, Inc. overvalued or undervalued?

As of 7 November 2025, the valuation grade for GE Healthcare Technologies, Inc. has moved from attractive to very attractive, indicating a strong improvement in its valuation outlook. The company appears undervalued, supported by a P/E ratio of 14, a PEG ratio of 0.39, and an EV to EBITDA ratio of 11.16, which are all favorable compared to its peers. For instance, Edwards Lifesciences Corp. has a significantly higher P/E ratio of 31.17, while Agilent Technologies, Inc. shows a P/E of 27.42, suggesting that GE Healthcare is trading at a discount relative to these competitors.
Despite the positive valuation metrics, GE Healthcare has underperformed relative to the S&P 500, with a year-to-date return of -6.56% compared to the index's 14.40%. This performance contrast may indicate that the market has not yet fully recognized the company's attractive valuation, reinforcing the view that it is currently undervalued.